We support a number of companies in their in-licensing activities, helping them develop strategies to leverage their strengths and achieve their corporate objectives. We also provide ongoing scouting support, working alongside the client’s internal efforts to generate a flow of new opportunities. Such activities include:
- working with the client’s global scouting team to identify companies and assets not yet appearing in industry pipeline databases
- contacting companies that fit our client’s criteria to ascertain their interest in a partnership
- targeted and regular attendance at partnering and scientific conferences
- scanning of new and recent literature to identify emerging opportunities
- outreach and networking with tech transfer offices, our industry contacts and licensing professionals
Our recent work has included supporting the Search & Evaluation team at a big pharma company to identify new opportunities in immune-oncology, orphan diseases, immunology, cardiovascular and fibrosis. We were also engaged by an emerging company backed by Versant Ventures and Celgene, for whom we conducted an extensive global search for first-in-class antibodies over a 12 month+ period. Many of our scouting relationships are ongoing and are all non-exclusive.
Case study: Pharma scouting for new antibody therapeutics
A well-capitalized biotech company focused on developing antibody therapeutics for cancer and fibrosis needed to find new preclinical assets to in-license, with a particular focus on immune-oncology. A far-reaching search would be required to find the right match.
Over the course of two years, we conducted a systematic, global pharma scouting project through channels that included scientific literature, databases of grants and patents; tech transfer offices and scientific societies.
We used several industry pipeline databases to identify and contact academics, biotech startups and existing companies with novel or fast-follower preclinical stage antibodies.
In addition to desk research, we attended numerous local and international networking and biotech partnering events to scout for opportunities on behalf of the client.
Having exhausted opportunities which had been published, we then wanted to find assets that were not yet in the public domain. We launched a scientific outreach campaign, sending individual, personalized emails to over 35,000 cancer researchers around the world.
We also deployed artificial intelligence and machine learning to scour and monitor the scientific literature to find scientific papers that described assets that fit our client’s criteria.
Our search and outreach identified several new in-licensing opportunities for our client, which are currently under due diligence or deal term negotiation.
Further case studies regarding Asset scouting are available here.
Related Case Studies
Screening for rare disease licensing opportunities
Our client, a commercial stage biotech company focused on rare and ultra-rare diseases was seeking to build its pipeline of development products. Whilst it had an established business...
Scouting for early-stage oncology opportunities
A listed North American company needed support with the identification, assessment and in-licensing of early-stage oncology assets. Solution We consulted our industry network and contacts and identified a...
Providing search and assessment support for oncology projects
A listed North American company needed hands-on support with the identification, assessment and in-licensing of early-stage oncology assets. Solution We consulted our industry network to identify a number...
Life Science Technology Scouting
Life science scouting Since 2013, Rob Johnson, based in Boston, MA, has been engaged by a well-capitalized Swiss pharma company to scout and identify early stage in-licensing opportunities from the New...
Scouting for medtech M&A opportunities
A rapidly growing European-headquartered specialty medtech company wanted to conduct a search for M&A opportunities in the interventional medicine arena. The objective was to find at least one...
Search for and assessment of stem cell therapies
A listed North American firm needed support with in-licensing or acquiring early-stage regenerative medicine programs. Solution We conducted a search for late-stage academic or seed-/early-stage commercial programs, introducing...